Allergan Licenses Molecular Partners' Anti-VEGF Protein For Ophthalmologic Indications
This article was originally published in The Pink Sheet Daily
Privately held Swiss firm gets $45 million upfront in deal for Phase II candidate being studied in wet age-related macular degeneration and diabetic macular edema.
You may also be interested in...
The widely dispersed array of developmental therapies for conditions such as non-small cell lung cancer and type 2 diabetes begs the question of whether it would make more sense to have a biopharmaceutical industry based on solution-focused companies approaching a single problem from multiple angles.
Allergan licenses a second novel product from Switzerland's Molecular Partners for ophthalmic indications and enters into a discovery alliance under which it has the option to license three further ophthalmic compounds.
With Botox now its biggest product, Allergan highlights moves to further the versatile drug’s expansion into new medical indications, as well as efforts to bolster the company’s traditional ophthalmic core, including advancing a pipeline candidate in the increasingly competitive wet-AMD field.